Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 110 filers reported holding Y-MABS THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,041 | -98.4% | 925 | -98.6% | 0.00% | -100.0% |
| Q1 2023 | $320,420 | -48.5% | 63,956 | -49.9% | 0.00% | -50.0% |
| Q4 2022 | $622,371 | -78.0% | 127,535 | +36.3% | 0.00% | -60.0% |
| Q1 2021 | $2,830,000 | +158.0% | 93,597 | +322.5% | 0.01% | +150.0% |
| Q4 2020 | $1,097,000 | -73.8% | 22,152 | -79.7% | 0.00% | -80.0% |
| Q3 2020 | $4,190,000 | +9.2% | 109,152 | +22.9% | 0.01% | +11.1% |
| Q2 2020 | $3,837,000 | – | 88,808 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 191,176 | $932,939 | 3.08% |
| Sofinnova Investments, Inc. | 2,194,278 | $10,708,077 | 0.64% |
| Artal Group S.A. | 400,000 | $1,952 | 0.11% |
| Polar Capital Holdings Plc | 1,991,929 | $9,720,614 | 0.08% |
| ASHFORD CAPITAL MANAGEMENT INC | 98,870 | $482,486 | 0.08% |
| Soleus Capital Management, L.P. | 87,182 | $425,448 | 0.06% |
| GSA CAPITAL PARTNERS LLP | 99,160 | $484 | 0.06% |
| Cormorant Asset Management, LP | 150,000 | $732 | 0.05% |
| CORNERCAP INVESTMENT COUNSEL INC | 48,233 | $235,377 | 0.04% |
| XTX Topco Ltd | 38,574 | $188,241 | 0.04% |